Osteoporosis: Subcutaneous Microchip for delivering drugs. Replace daily injection, in some cases must be women diagnosed with osteoporosis, a small device the size of a chip and, implanted under the skin at the waist, frees the required dose. Is the new and revolutionized medical progress, thanks to new technologies, helps to improve the treatment of one of the most common diseases among women and, above all, quality of life.
A small subcutaneous microchip is about to revolutionize the treatment of osteoporosis, as it will allow patients to forget the daily injections uncomfortable sometimes requires diagnosis. This chip, which is placed under the skin at the waist area and has already been tested in women with osteoporosis (clinical trials), free for twenty days, the dose required for treatment, avoiding having to get a shot each day. The revolutionary invention has been developed by the Massachusetts Institute of Technology and, so far, the results of its implementation in eight women are satisfactory. Among other features, the new administrator of drugs is controlled via wireless (remote control of both the dose and time) and contains within it the necessary doses of teriparatide, a drug to treat osteoporosis, and to be releasing as needed of the patient.
During the trial, whose results were published in the Science Translational Medicine and presented at the meeting of the American Association for the Advancement of Science held in Canada, released more than 130 doses with success, so we get the effects of the drug managed to be good. Furthermore, the microchip after being implanted, did not produce side effects in patients, so we get the same therapeutic effect than injections and favoring the production of bone tissue. The chip implantation was performed under local anesthesia in an intervention of only twenty minutes.
For now, the work of researchers allows the release of the dose during a specified period. The goal now is to keep improving the technology and applications of the microchip can be implanted to the patients for longer, ie injections can be released for at least a year. But not only the test opens the way to further improve the processing and dispensing of drugs, but could be a response to control glucose levels or insulin in the case of people diagnosed with diabetes.
The company MicroCIPS, colaborada the trial, has announced it hopes to market this new drug dispenser before 2014, because you first need to confirm the results with a higher sampling of patients to make sure no errors in the administration of the dose. (what is osteoporosis ?) learn more !!!